



**Josua Jordi Ph.D. - CEO**


RESI Partnering Week

November 2021

[josua.jordi@eracal.ch](mailto:josua.jordi@eracal.ch)

[www.eracal.ch](http://www.eracal.ch)

# Obesity is a serious chronic disease




- Life expectancy reduced by 4 years
- Social prejudice & diverse morbidities (diabetes type 2, NASH, ...)



- \$ >3 Trillion is the annual global cost of obesity
  - \$ >270M Gubra (preclinical, 2021)
  - \$ >200M NGM (preclinical, 2018)
  - JV-GPR75 Regeneron (preclinical, 2021)




# Standard of care is unsatisfactory



- 4. June 2021, FDA approval for SC injected, 2.4mg once weekly semaglutide (Novo Nordisk)


# Orally active new chemical family

## Diet-induced obese-mice



- new chemical entity, drug-like properties, structure-activity relationship defined with >30 compounds
- high permeability, low-clearance compound with linear exposure-effect relationship
- safety – no effect on locomotion 3x dose, stage-appropriate *in vitro* safety profile
- on-going – dose-escalation studies, expand to higher species, target deconvolution

# A unique *in vivo* phenotypic platform



>100'000  
zebrafish larvae




HARVARD  
UNIVERSITY

# Bold team with world-class advisors



**Dr. J. Jordi**  
CEO & Co-Founder



**Dr. S. Breitler**  
COO & Co-Founder



## Board of Directors



**Prof. HR. Künzle**



**Dr. A. Kessler**



**Dr. B. Ernst**



**Dr. M. Sidler**



## Advisors



**Dr. H. Böttcher**




**Dr. G. Meyer**




**Prof. T. Lutz**



**Prof. F. Engert**



# First-in-human planned in H1 2024



→ **clinical candidate selection**

→ target ID  
→ biomarkers

→ energy expenditure program

→ phase 2  
→ advance new programs



[josua.jordi@eracal.ch](mailto:josua.jordi@eracal.ch)



Multibillion dollar  
indication

Orally active and  
potent appetite  
suppressor

Creative *in vivo*  
platform

Bold team  
with  
world-class  
advisors